Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial ; volume:30 ; number:7 ; day:13 ; month:5 ; year:2024 ; pages:2049-2057 ; date:7.2024
Nature medicine ; 30, Heft 7 (13.5.2024), 2049-2057, 7.2024
- Creator
-
Ryan, Donna H.
Lingvay, Ildiko
Deanfield, John
Kahn, Steven E.
Barros, Eric
Burguera, Bartolome
Colhoun, Helen M.
Cercato, Cintia
Dicker, Dror
Horn, Deborah B.
Hovingh, G. Kees
Jeppesen, Ole Kleist
Kokkinos, Alexander
Lincoff, A. Michael
Meyhöfer, Sebastian M.
Oral, Tugce Kalayci
Plutzky, Jorge
Beek, André P. van
Wilding, John P. H.
Kushner, Robert F.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41591-024-02996-7
- URN
-
urn:nbn:de:101:1-2410052105572.100507378938
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ryan, Donna H.
- Lingvay, Ildiko
- Deanfield, John
- Kahn, Steven E.
- Barros, Eric
- Burguera, Bartolome
- Colhoun, Helen M.
- Cercato, Cintia
- Dicker, Dror
- Horn, Deborah B.
- Hovingh, G. Kees
- Jeppesen, Ole Kleist
- Kokkinos, Alexander
- Lincoff, A. Michael
- Meyhöfer, Sebastian M.
- Oral, Tugce Kalayci
- Plutzky, Jorge
- Beek, André P. van
- Wilding, John P. H.
- Kushner, Robert F.
- SpringerLink (Online service)
Other Objects (12)
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Semaglutide in Obesity: Unmet Needs in Men
Semaglutide
Semaglutide treatment of hypothalamic obesity – a real-life data study
Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity
The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery—a Retrospective Analysis
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
Cost-effectiveness of semaglutide 2.4 mg in chronic weight management in Portugal
Management of obesity with semaglutide or metformin in patients with antipsychotic-induced weight gain (MOSA): a non-randomised open-label pilot study
Semaglutide Treatment in a Patient with Extreme Obesity and Massive Lymphedema: A Case Report
Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Semaglutide in Obesity: Unmet Needs in Men
Semaglutide
Semaglutide treatment of hypothalamic obesity – a real-life data study
Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity
The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery—a Retrospective Analysis
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
Cost-effectiveness of semaglutide 2.4 mg in chronic weight management in Portugal
Management of obesity with semaglutide or metformin in patients with antipsychotic-induced weight gain (MOSA): a non-randomised open-label pilot study
Semaglutide Treatment in a Patient with Extreme Obesity and Massive Lymphedema: A Case Report
Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Semaglutide in Obesity: Unmet Needs in Men
Semaglutide
Semaglutide treatment of hypothalamic obesity – a real-life data study
Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity
The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery—a Retrospective Analysis
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
Cost-effectiveness of semaglutide 2.4 mg in chronic weight management in Portugal
Management of obesity with semaglutide or metformin in patients with antipsychotic-induced weight gain (MOSA): a non-randomised open-label pilot study
Semaglutide Treatment in a Patient with Extreme Obesity and Massive Lymphedema: A Case Report